Editorial: Natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy

Editorial: Natural products modulate the sensitivity of cancer to anti-PD-1 based immunotherapy

Bibliographic Details
Main Authors:	Jean Christopher Chamcheu, Qian Ba, Hang Ma
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-06-01
Series:	Frontiers in Pharmacology
Subjects:	natural products immunotherapy immune checkpoint blockade cancer immunotherapy anti-PD-1/PD-L1 sensitivity
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1232456/full

Similar Items

PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
by: Jan Willem Kleinovink, et al.
Published: (2017-04-01)

Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms
by: Arta M. Monjazeb, et al.
Published: (2021-02-01)

Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura
by: James T. Boothe, et al.
Published: (2017-11-01)

Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma
by: Huiyu Yan, et al.
Published: (2023-10-01)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
by: Junyu Long, et al.
Published: (2017-08-01)

Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
by: Vida Vafaizadeh, et al.
Published: (2020-03-01)

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
by: Yongshuai Jiang, et al.
Published: (2019-05-01)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01)

Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
by: Lucy Guan, et al.
Published: (2023-03-01)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
by: Ewa Surmiak, et al.
Published: (2021-10-01)

Cancer immunotherapies targeting the PD-1 signaling pathway
by: Yoshiko Iwai, et al.
Published: (2017-04-01)

Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells
by: Hadia Farrukh, et al.
Published: (2021-05-01)

Immunotherapy in non-small cell lung cancer: Past, present, and future directions
by: Salman R. Punekar, et al.
Published: (2022-08-01)

Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy
by: Aayushma Gautam, et al.
Published: (2021-09-01)

Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy
by: Tao Wang, et al.
Published: (2022-05-01)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
by: Xi Chen, et al.
Published: (2020-05-01)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
by: Hiroo Katsuya, et al.
Published: (2023-11-01)

Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
by: Tingxuan Gu, et al.
Published: (2023-05-01)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
by: Jessica M. Konen, et al.
Published: (2019-04-01)

Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress
by: Zin W. Myint, et al.
Published: (2017-04-01)

Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review
by: Huilan Zheng, et al.
Published: (2023-06-01)

Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
by: Jia-Wen Cui, et al.
Published: (2024-02-01)

The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF-β as a Companion Target for Checkpoint Blockade Immunotherapy
by: Bjarne Bartlett, et al.
Published: (2021-10-01)

Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway
by: Grace Wakabayashi, et al.
Published: (2019-12-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)

Perioperative immunotherapy for esophageal squamous cell carcinoma
by: Dan D. Wei, et al.
Published: (2024-02-01)

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
by: Zachary S. Buchwald, et al.
Published: (2018-12-01)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
by: Yu Yuan, et al.
Published: (2021-02-01)

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy
by: Katarzyna Tomela, et al.
Published: (2023-03-01)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
by: Angelo Borsarelli Carvalho Brito, et al.
Published: (2021-04-01)

Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis
by: Edyta Zyla, et al.
Published: (2021-08-01)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
by: Shaomeng Chen, et al.
Published: (2021-09-01)

Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer
by: Besan H. Al-Saafeen, et al.
Published: (2022-12-01)

PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
by: Tianrui Yang, et al.
Published: (2021-02-01)

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy
by: Xinran Gao, et al.
Published: (2024-03-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner
by: Honghong He, et al.
Published: (2021-01-01)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
by: Ofek Mussafi, et al.
Published: (2022-08-01)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
by: Roman Groisberg, et al.
Published: (2017-12-01)